Alpha Tau Medical Ltd. Share Price

Equities

DRTS

IL0011839383

Investment Holding Companies

Real-time Estimate Cboe BZX 20:18:58 29/04/2024 BST 5-day change 1st Jan Change
2.415 USD +0.42% Intraday chart for Alpha Tau Medical Ltd. -1.02% -19.77%
Sales 2024 * 75K 5.97M Sales 2025 * 1.37M 109M Capitalization 168M 13.34B
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 2,234 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 122 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 121
Yield 2024 *
-
Yield 2025 *
-
Free-Float 74.28%
More Fundamentals * Assessed data
Dynamic Chart
Alpha Tau Medical Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Alpha Tau Medical Ltd. Announces Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer CI
Alpha Tau, HekaBio Seek Japan's Premarket Approval of Alpha-Radiation Therapy for Head, Neck Cancer MT
Alpha Tau Medical Ltd. Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer CI
Piper Sandler Adjusts Alpha Tau Medical's Price Target to $8 From $12, Keeps Overweight Rating MT
Alpha Tau Medical Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Alpha Tau Medical Ltd. Announces Stephen M. Hahn Joins Scientific Advisory Board CI
Alpha Tau Medical Treats First Patient With Advanced Inoperable Pancreatic Cancer in Israel Clinical Trial MT
Alpha Tau Medical Ltd. Treats First Patient with Advanced Inoperable Pancreatic Cancer At Israel's Hadassah Medical Center CI
Alpha Tau Medical Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Alpha Tau Medical Says Alpha DaRT Shows Long-Term Safety, Tumor Control Outcomes for Cancer Patients From Multiple Trials MT
Traders on Edge Amid Elevated Bond Yields, Driving Premarket Losses for US Equity Futures MT
Top Premarket Gainers MT
Alpha Tau Medical Ltd. Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT CI
Alpha Tau Medical Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
More news
1 day+0.42%
1 week-1.02%
Current month-18.14%
1 month-16.72%
3 months-23.09%
6 months-27.92%
Current year-19.77%
More quotes
1 week
2.15
Extreme 2.1501
2.56
1 month
2.15
Extreme 2.1501
2.95
Current year
2.15
Extreme 2.1501
3.40
1 year
2.15
Extreme 2.1501
4.80
3 years
2.15
Extreme 2.1501
20.65
5 years
2.15
Extreme 2.1501
20.65
10 years
2.15
Extreme 2.1501
20.65
More quotes
Managers TitleAgeSince
Founder 84 31/10/15
Founder 76 31/10/15
Chief Executive Officer 54 31/10/15
Members of the board TitleAgeSince
Director/Board Member 68 28/02/22
Director/Board Member 54 31/12/15
Director/Board Member 57 31/12/17
More insiders
Date Price Change Volume
29/04/24 2.415 +0.42% 17 865
26/04/24 2.405 +0.21% 145,122
25/04/24 2.4 -3.61% 75,817
24/04/24 2.49 -0.40% 2,826
23/04/24 2.5 +2.46% 43,883

Delayed Quote Nasdaq, April 29, 2024 at 08:03 pm

More quotes
Alpha Tau Medical Ltd is an Israel-based medical technology company that focuses on research, development and commercialization of Alpha DaRT Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT) for the treatment of solid cancer. Company's technology relies on the diffusion of atoms that emit alpha particles within the tumor tissue, and enables alpha radiation to reach the the entire tumor. Precise amounts of radioactive radium-224 affixed that emit short-range alpha radiation enables to damages and kills cancer cells within a short period of time. The Company has one subsidiary Healthcare Capital Corp.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.405 USD
Average target price
9.25 USD
Spread / Average Target
+284.62%
Consensus

Quarterly revenue - Rate of surprise